ABCDEFGHIJKLMNOPQRSTUVWYZAAABACAFAGAHAIAJAKALAMANAOAPAQARASATAUAVAWAXAYAZBABBBCBDBEBFBGBHBIBJ
1
[how to sort/filter]
[* = see notes col]
[gray = older info]
is it
aging?
aging mission?core aging area?multiple aging diseases?core aging confs?is it
rejuvenation?
operating statusshort summary
(intended to be objective, usually from company website, edited for brevity)
clinical stage (& link to pipeline)pipeline image
[if not clickable, use clin stage link]
Tx or Dxcategories
(map to SENS & hallmarks)
diseases/ indications
[not comprehensive or canonicalized]
species (beside humans)clinical trialstargets / pathway / MoAsmodalitiesregulatory categoryteamgeo(s)public?ticker Y!market cap (M)employees, Y! publicsemployees LIyear foundedtot. raised (US$M)raised other currpharma partners/ investorsproduct namespubs/ papersas of (last full row update)date added to listnotesfull overall scorescore w/o 4p focusaging focus score4-prong focus score (confs wght less)operating status scorepipeline image bonusclin. stage score# employees scoretotal raised / valuation scoreTx > Dxpharma > supplements / unregpubs bonuscheck for all 4 noupdated since Jul 2024?
2
Calicoyesyesyesyesyesoperatingbroad mission to improve health and longevity using technology to advance biological scienceph.2/3 trials (full list of trials)Txbig industrial R&DALS, cancer, vanishing white matter10eIF2BpharmaArthur D. Levinson, Cynthia KenyonSFno3632013$2,500Abbviemany2024-07-25201917 PIs listed as of Jul'24. Initially funded/created within Google/Alphabet.13.013.01.01.01.01.02.33.74.91.01.01.201
3
Stealth BioTherapeuticsyesyesyesyesnonooperatingmitochondria platform for age & genetic mito diseases; first a peptide to stabilize inner mito membraneph.3 trials
TxmitochondriaAMD, DMD, ALS, mito-neuroDs29cardiolipinpeptides, small moleculespharmaReenie McCarthyBostonno*662007$191Elamipretideseveral publications2024-07-162019*Was public, but taken private in 2022.9.911.01.00.91.01.13.32.63.31.01.01.201
4
Altos Labsyesyesyesyes*yesyesoperatingcell rejuvenation by partial/epigenetic reprogramming; big & academic-like: aiming to be "Bell Labs" of biopre-clinicalTx, Dxepigenetic, big industrial R&DOSKMpharmaHal Barron, Rick Klausner, Hans Bishop, Juan Carlos I. Belmonte, Wolf Reik, Jodi Nunnari
SF; SD;
Cambridge, UK
no5272021$5,5602024-07-122022-06-19*Diseases not specified but mission clearly includes multiple age-related diseases. 22 PIs listed as of Jul'24. Jul'24 Rick Klausner said they extended old mice lifespan 25% w/ 1 injection of Yamanaka formulation in a 1000 mouse study. Jeff Bezos widely reputed to be an investor.9.89.81.01.01.01.00.53.95.41.01.01.001
5
BioAge Labsyesyesyesyesyesnooperatinghuman long-term biobanks + multiomics + AI drug platform for metabolic aging w/ APJ & NLRP3 leadsph.2 trials
Txmetabolism, inflammationobesity, muscle atrophy, neuroinflam4APJ, NLRP3drugspharmaKristen Fortney, Eric Morgen, Paul RubinSFyesBIOA$16258872015$294Lilly*main pubs; paper2024-07-122019Lead APJ/apelin program now listed as being for obesity (arguably not age related) but previously described as being for muscle atrophy which is age-related & APJ clearly related to core aging pathways. *Partnered with Lilly for the obesity phase 2 trial & Lilly participated in the early 2024 $170M series D round.9.89.81.01.01.01.12.22.83.21.01.01.201
6
Juvenescenceyesyesyesyesyesoperatingumbrella company focused on aging w/ both (ketone) supplement & pharma programs (PAI-1, GDF15, CD38, ketones, & plasmalogens, autophagy, liver & limb regen)commercial, ph.2a trials*
Txumbrella companyfibrosis, muscle wasting in cancer, RA, HF, dementia2PAI-1, GDF15, CD38, plasmalogensdrugs & others, supplementpharma, nutraceuticalsRichard Marshall, Greg Bailey, Jim MellonLondon, NYCno282016$308papers2024-07-272019*Subco LyGenesis in ph.2a; in-house program in ph.1 as of Dec'24. Portfolio companies include BHB Therapeutics, BOPZ Nutrition, Chrysea, LyGenesis, Morphoceuticals, Relation Therapeutics, & Souvien Therapeutics.8.58.51.01.01.01.11.52.13.61.01.01.201
7
Mesoblastyesnoyesyes*noyesoperatingallogeneic mesenchymal stem cells for multiple (esp inflammatory) diseasesapproved (ph.3 success)*
Txstem cells / allogeneicHF, deg-discD, Covid (& non-agingDs)42MSCscell therapypharmaSilviu ItescuNYC, MelbourneyesMESO$2,14083772004$452Revascor, Ryoncil (Remestemcel-L)many2024-07-122019*Focus on non-age-related conditions too, but stem-cells clearly applicable to aging diseases too & multiple unrelated aging diseases in their pipeline. With partners they've received approval for some treatments in Japan & Europe for non-aging diseases. Jul'24 BLA submitted to FDA for pediatric steroid-refractory acute graft versus host disease (SR-aGVHD), a notable regulatory step even if not primarily age-related.8.514.21.00.61.01.14.42.74.81.01.01.201
8
Scholar Rockyesnoyesyesnonooperatingplatform for targeting precursors of growth factors including myostatin & TGFβph.3 trials
Txmetabolism, inflammation, cancermuscle atrophy, cardiometabolic, cancer, fibrosis6myostatin, TGFβmonoclonal antibodiespharmaJay BackstromBostonyesSRRK$3,6801501742012$443Apitegromabpapers & posters2024-07-142022-06-28Named after scholar rocks, unusual rocks appreciated by scholars in east Asia (esp China) for their unusual & intricate shapes that resemble protein shapes.8.413.91.00.61.01.13.33.25.11.01.01.201
9
Celularityyesyesyesyesnoyesoperatingallogeneic placental-derived cell therapies (MLASCs, CAR-T, NK cells) for aging, degenerative, immune diseases, cancer; also biomaterialsph.1/2 trials
Txstem cells / allogeneic, senescencecancer, muscleDs, autoimmuneDs17MLASCs, CAR-T, NK cellscell therapypharmaRobert HaririNYCyesCELU$592551722016$400posters in sub pages2024-07-282019Added a senolytic program (based on NK cells) relatively recently (as of 2024). Also run income generating programs to bank placental stem cells and to treat burns & wounds, with projected $40M revenue, as of 2019.7.88.71.00.91.01.11.53.22.51.01.01.201
10
Alkahest
(owned by Grifols)
yesyesyesyesyesyesacquired*, operating independlyleads from blood proteins that go up or down with age, eg young blood fractionsph.2 trials
Txcell communicationAD, PD, wAMD, ESRD MCI13drugs, biologics, blood fractionspharmaEsther Rawner, Tony Wyss-CoraySFpublic owner$265592014$50Grifolspapers2024-07-262019*Aquired by Grifols (remaining 55% for $146M) Sep'20, but website still operating indepedently.7.47.41.01.00.81.12.22.53.51.01.01.201
11
Immunis Inc.yesyesyesyesyesyesoperatingstem-cell secretome products for age-driven immune dysfunction, muscle regeneration & metabolismph.2 trials
Txstem cellsmuscle atrophy, woulds, metadb, neuroDs, immuneDs3secretome cocktailpharmaHans KeirsteadLAno172018$32IMMUNA2024, 2021 papers2024-08-182023-01-24Not to be confused with Immunis.AI.7.47.41.01.01.01.12.21.82.21.01.01.201
12
Juvena Therapeuticsyesyesyesyesyesyesoperatingcomputationally-driven platform based on human stem cell secreted proteins engineered into novel biologicsph.1 trials
Txstem cells, cell communicationDM1, obesity, fibrosis, OA1biologicspharmaHanadie Yousef, Jeremy O'ConnellSFno432017$49.2click pubs2024-08-0420197.07.01.01.01.01.11.12.32.41.01.01.201
13
Biosplice (was Samumed)yesnoyesyesnoyesoperatingalt splicing by targeting CLK/DYRK kinases w/ small molecules (came to this via work on Wnt pathway) to eliminate harmful proteins, 1st for OA, onco, neuroph.3 trials
Txsplicing, proteostasis?OA, deg-discD, cancer, AD, TBI, tauDs22CLK/DYRK family kinasessmall moleculespharmaCevdet SamikogluSDno422008$778Lorecivivint, Cirtuvivintseveral2024-07-152019Formerly called Samumed.7.011.71.00.61.01.13.32.34.11.01.01.201
14
Life Biosciencesyesyesyesyesyesyesoperatingepigenetic reprogramming via OSK and small molecules for chaperone mediated autophagypre-clinical
Txepigenetic, autophagyeyeDs, neuroDsOSK, LAMP2Agene therapy, small moleculespharmaDavid Sinclair, Jerry McLaughlinBostonno222017$207papers2024-08-042019Originally an umbrella company focused on aging with many notable professors in the field involved.6.96.91.01.01.01.10.61.93.31.01.01.201
15
Cambrian Bioyesyesyesyesyesoperatingumbrella company focused on aging w/ leads in AMPK, mitochondria, mTOR, & more.ph.1b trials*
Txumbrella companycardiometabolic, cancer0*AMPK, mTORdrugspharmaJames PeyerNYCno322019$1602024-07-132020-05-03*Pipeline image shows ph.1/2a for ATX-304 & Amplifier website pipeline shows just ph.2 but can't find trial on clinicaltrials.gov under either company name or ATX-304 as of Jul'24 so using press release of 1b. Portfolio companies include: Amplifier Tx, Isterian, Oviva Tx, Telos Bio, Tornado Tx, & Vita Tx.6.46.41.01.01.01.11.12.23.21.01.01.001
16
Retro BiosciencesyesyesyesyesyesyesoperatingHSC reprogramming, autophagy enhancement, & apheresis-inspired microglia therapeutics w/ goal to extend healthspan 10yrspre-clinical
Txepigenetic, autophagy, stem cellsAD, OA, hearing losssmall molecules, stem cells, TFspharmaJoe Betts-LaCroixSFno572021$1802024-08-012021-05-116.36.31.01.01.01.10.62.53.21.01.01.001
17
Rubedo Life Sciencesyesyesyesyesyesyesoperatingtarget pathological cells that drive aging, esp senescent cells, using AI, single cell seq, & precision targeting through computational drug design inc pro-drugspre-clinical
TxsenescenceAD, psoriosis, IPF, NASH, cancer, sclerosisGPX4small moleculespharmaMarco QuartaSFno282018$54papers2024-08-062019Announced strategy multi-year partnership with skin care giant Beiersdorf, to develop aging skin products esp senolytics, Apr'24.6.16.11.01.01.01.10.62.12.51.01.01.201
18
Turn
Biotechnologies
yesyesyesyesyesyesoperatingmRNA epigenetic reprogramming to restore capabilities lost with age via OSKMLNpre-clinical
Txepigeneticskin conditions, OA, glaucoma, frailty/sarcopeniaOSKMLNRNApharmaAnja Krammer, Vittorio SebastianoSFno332018$30.1key paper*2024-08-102019*OSKMLN shown to reverse 8 of the 9 hallmarks of aging, all except telomeres.5.85.81.01.01.01.10.62.22.11.01.01.201
19
Geroyesyesyesyesyesoperatingphysics / dynamical systems based modeling of aging via deep nets AI on whole-exome sequencing & digital biomarkers licensing/partnering & AI drug developmentpre-clinical
Tx, DxCVD, cancer, fibroticDsdrugspharmaPeter Fedichevno1322018$6Pfizerpapers2024-08-1520195.85.81.01.01.01.10.63.01.21.01.01.201
20
Alnylamborderline*noyesyesnonooperatinggeneral platform to develop RNA interference (RNAi) therapieus to silence disease-specific genes, with broad application to many age-related disease areasapproved (ph.3 success)
Txproteostasis(h)ATTR(-CM), AD, HD, ALS, T2D, MASH, NAFLD, hypercholesterolemia, hypertension82ATTR, APP, PCSK9, AGT, HTT, SOD-1, HSD17B13siRNApharmaYvonne Greenstreet, Kevin FitzgeraldBostonnoALNY$40,566210024422002>$100MOnpattro, Amvuttra, Leqvioscience presentations2025-02-022024-08-15*Borderline: Broad product pipeline & mission of RNAi therapeutics makes it more like a modality-themed generic med-to-big pharma rather than aging company, but pipeline includes majority age-related diseases with tx for several misfolded proteins (ATTR, AD, HD, ALS) & multiple CVD related diseases (ATTR, hypercholesterolemia, & hypertension) plus misc age-related liver/metabolic (MASH, T2D, NAFLD).5.79.50.50.61.01.14.44.86.61.01.01.201
21
Elevianyesyesyesyesyesoperatingrecombinant GDF11, first for strokepre-clinical
Txcell communicationstroke, pancreatitis, wound healing, cardiometabolicDsGDF11biologicspharmaMark AllenBostonno112017$64bottom of page2024-08-1220195.65.61.01.01.01.10.61.52.61.01.01.201
22
Attralusyesnoyesyesnoyesoperatingpan-amalyoid diagnostics & therapeutics for amyloid diseases: systemic amyloidosis (ATTR & AL) & neurodegenerative diseases w/ misfolded proteinsph.2 trials
Tx, Dxproteostasissystemic amyloidosis, AD, PD3ATTR, AL, Aβ, Tau, α-synucleinpeptidespharma, reg DxMark TimneySFno312019$198posters & pubs2024-10-192020-01-04Formerly called Aurora Bio (not to be confused with several other companies called Aurora Bio: Sydney based medical device maker Aurora BioScience, cancer company Aurora BioPharma, drug discovery system company Aurora Biosciences, acquired by Vertex in 2001).5.59.11.00.61.01.12.22.13.31.01.01.201
23
Longeveronyesyesyesyesnoyesoperatingallogeneic mesenchymal stem cells f/ bone marrowph.2 trials
Txstem cells / allogeneic, mitochondria*frailty, AD, metabolicDs, ARDS, HLHS10MSCscell therapypharmaWa’el Hashad, Joshua HareMiamiyesLGVN$2223262014$34.0Lomecel-B2024-07-282019*Primarily stem cells, but MoA page notes that mitochondrial transfer (transplant) is one of the MoAs (injected SCs donate mitochondria).
Lomecel-B got RMAT designation from FDA (first cell therapy to get this for AD) as of Jul'24.
5.66.21.00.91.01.12.22.01.91.01.01.001
24
Athersys Incyesnoyesyesnoyesoperatingallogeneic stem cellsph.3 trials (completed in Japan)
Txstem cells / allogeneicstroke, ARDS, trauma, neuroDs, CVD, lungDs4cell therapypharmaDaniel CamardoCleveland, OHno*371995$209MultiStem2024-08-012019*Was public but delisted in 2023. RMAT designation in stroke.5.38.91.00.61.01.13.32.23.31.01.01.001
25
Centara Labs (was Rejuveron)yesyesyesyesoperatingumbrella company focused on agingph.2a trials*
Txumbrella companyRP, dAMD, cancer, sacropenia, IPF, neuroDs0pharmaAksana Labokha, Christian AngermayerZurichno142019$862024-08-022021-05-06*Endogena pipeline says 2a trials as of Aug'24. Portfolio companies include Endogena, Rejuvenate Biomed, Rejuveron Senescence Tx, Rejuveron Telomere Tx, Rejuveron Vascular Tx, Boost Neuro.5.35.91.00.91.01.11.51.62.81.01.01.001
26
Rejuvenate Biomedyesyesyesyesnonooperatingplatform for finding synergistic combinations of existing approved drugs for age-related diseases, lead combines metformin & galantamine (an AD drug)ph.1 trials*
Txbroad platform, metabolism, inflammationsarcopenia, OA0AMPK, AChEsmall moleculespharma / existing combosAnn BeliënBelgiumno142017$231 paper for lead2024-09-042023-05-29*Pipeline diagram makes it look like its in phase 2 already, but can't find the trials on clinicaltrials.gov site.
Rejuveron sub-company. Not to be confused with Rejuvenate Bio.
5.15.61.00.91.01.11.11.62.01.01.01.201
27
Vaxxinity (website removed all info intentionally*)yesyesyesnooperating*synthetic peptide vaccines for chronic diseases inc. AD, PD, migraine, & hypercholesterolemia (& infections inc Covid)ph.3 trialsTxproteostasisAD, PD, CVD, Covid9Aβ, α-synuclein, cholesterolpeptide vaccinepharmaFlorida, NYCno*632014$9.3paper; old paper2024-08-042019*Was public (ticker VAXX) but voluntarily delisted May'24 & removed all info from main website as of Aug'24 (says it's gone dark, but still there), but investor relations website still has info at ir.vaxxinity.com inc. press releases thru Jun'24. FAQ about delisting explains rationale for not reporting public co info but not for website showing less info than a pre-public co. Formerly called United Neuroscience.5.18.41.00.61.01.03.02.61.41.01.01.201
28
OrsoBioyesnoyesyesnonooperatingrestore energy homeostasis for metabolic disorders via regulating lipid biogenesis & mitochondria entry, mito protonophores (uncoupling), & ↑ NAD+ synthesis ph.2 trials*
Txmetabolism, mitochondriaobesity, T2D, NASH, hypertriglyceridemia4ACC2, LXR, ACMSDsmall moleculespharmaMani SubramanianSFno172021$129papers2024-09-112024-09-11*Pipeline diagram shows phase1, but science page & clinical trials show phase 2, as of Sep'24.5.08.41.00.61.01.12.21.83.01.01.01.201
29
Aeovianyesyesyesyesnonooperatingselective mTORC1 inhibitors & (mostly CNS penetrant) inhibitors of CD38 (which degrades NAD+)ph.1 trials
Txmetabolism / mTOR, mitochondria / NAD+epilepsy, neuroDs, metabolicDs1mTOR, CD38small moleculespharmaSFno102012$872024-07-272019Mar'24 raised $50M led by Hevolution (first public Hevolution lead investment). Formerly called Aeonian.4.85.31.00.91.01.11.11.42.81.01.01.001
30
Ichor Life SciencesyesyesyesyesyesyesoperatingCRO & umbrella company focused on agingcommercial, pre-clinicalTxCRO, umbrella company, intracell junkAMDsmall molecules, biologicspharmaKelsey MoodySyracuse, NYno382013$4.5several2024-08-0320192021: shifted to focus on service (CRO) offerings rather than being primarily an umbrella development company (previously called Ichor Therapeutics), but still has an aging emphasis & portfolio of sub-companies. Portfolio companies include: LysoClear, MitoChem, Auctus Bio, & Lento Bio.4.64.61.01.01.01.00.52.31.11.01.01.201
31
Olatecyesnoyesyesnonooperatingoral small molecule NLRP3 inhibitor that lowers inflammation via effects on IL‑1β & IL-18, with some advantages over directly targeting thoseph.2/3 trialsTxinflammationgout flare, cancer, T2D, PD, HF, OA10NLRP3small moleculespharmaDamaris B. SkourasNYC, Bostonno152003$40dapansutrilepapers2024-11-232024-08-154.67.61.00.61.01.02.31.72.31.01.01.201
32
Gordian Biotechnologyyesyesyesyesoperatingmosaic (pooled in vivo) screening in animals best representing target diseases w/ full transcriptome AI analysispre-clinicalTxbroad platformgene therapypharmaFrancisco LePort, Martin Borch Jensen
SFno372018$60a few papers + talks 2024-08-012019Not to be confused with several other companies named Gordian, in IT, investment banking, & staffing/recruiting.4.56.41.00.71.01.00.52.22.61.01.01.201
33
Biophytisyesyesyesnooperatingdrug discovery platform for aging & degenerative conditions based on discovery from plant secondary metabolites, mostly via MoAs that increase resilienceph.3 trials*
Txbroad platformsarcopenia, dAMD, MD, obesity, Covid3MasRsmall moleculespharmaStanislas VeilletParisyesALBPS.PA$322252006$37Ruvembri, Sarconeos,Macuneossarcopenia; eye2024-07-282019*Phase 3 Covid trial seems to have succeeded based on this press release. Pipeline diagram makes it look like regulatory approval is in progress.4.57.41.00.61.01.13.32.00.91.01.01.201
34
Loyalyesyesyesyesyesnooperatingdrug(s) to treat aging in dogs, by lowering IGF-1 & other metabolism interventionsvet clinical trialsTxmetabolismdogsIGF-1drugsveterinaryCeline HaliouaSFno642019$150near page bottom2024-07-132019-12-19The company got the FDA to formally accept a clinical trial design using lifespan as an endpoint, a significant regulatory hurdle for the field.4.34.31.01.01.01.01.52.63.11.00.51.201
35
Mitotechyesyesyesyesyesnooperatingmito-targeted small molecules for oxidative stress & lipid peroxidation (cardiolipin peroxidation inhibitors), 1st for eye diseases then neuro & metabolic conditionsph.3 trialsTxmitochondriadAMD, other eye diseases, later AD, PD, ALS, NASH3cardiolipinsmall moleculespharmaNatalia PerekhvatovaRussiano82009unknownVisomitin, SkQ12024-09-032022-06-204.34.31.01.01.01.03.01.30.01.01.01.001
36
Oisin Biotechnologiesyesyesyesyesyesyesoperatingrepeat doseable genetic medicines (DNA or RNA) for aging (frailty via muscle, kill fat cells & senescent cells) via non-viral gene therapy w/ good non-liver distributionpre-clinicalTxsenescence, genomicfrailty, obesity, cancerfollistatin, fat cells, p16, p53gene therapy / non-viralpharmaMatthew Scholz, John LewisSF, Seattle, SDno172014$252024-08-052019First close of $15M series A announced Jul'2024. Spun out OncoSenX for cancer (not on this list since devoted only to cancer, but for the purposes of this list the 2 companies are best considered as one). Uses Entos Pharma's non-viral gene therapy delivery platform.4.34.31.01.01.01.00.51.82.01.01.01.001
37
Alchemab Therapeuticsyes*noyesyesnooperatingdrug discovery platform based on sequencing B cells of long-term survivors, understanding the antibody targets & feeding that into a comput. drug discovery enginepre-clinical
Txbroad platformFTD, ALS, AD, Huntington's, cancer**CD33, Huntingtin, Complement Factor HantibodiespharmaYoung KwonCambridge, UKno622019$86check box for pubs2024-08-022021-05-11*See this piece for discussion of the platform's relationship to longevity.
**Besides pipeline indicationts, also has samples for ALS, more cancers, Covid, & centenarians.
4.27.11.00.61.01.10.62.62.81.01.01.201
38
Denali Therapeuticsonly neuro*no*yesyesnooperatingdrug discovery for neurodegeneration, optimized for brain delivery, guided by genetics & biomarkers, but also lysosomal storage disesaes & systemic inflam.ph.3 trials
Txautophagy, inflammationPD, FTD, Hunter's, ALS, AD, MS, inflammation22eIF2B, iduronate 2-sulfatase, LRRK2, progranulin, sulfamidase, alpha-L-iduronidasesmall molecules, biologicspharmaRyan WattsSFyesDNLI$2,0593754222015$1,100papers2024-08-012019*Mission is neurodegeneration & lysosomal storage diseases. They also have a program on systemic inflammation, but almost all indication are neuro.4.27.10.50.61.01.13.33.84.71.01.01.201
39
Blue Rock Therapeutics (owned by Bayer)yesnoyesyesnoyesacquired*, operating independ.universal pluripotent stem cell lines produced & differentiatied at scale for allogeneic cell therapies for neuro-/cardio-/immunology/moreph.1 trials
Txstem cells / allogeneicPD, neuroDs, dAMD, HF3various cell types (see pipeline)cell therapypharmaSeth EttenbergBoston, Torontopublic owner$1,0144892016$225Bayer
bemdaneprocel
2024-07-252020-01-05*Acquired by Bayer (remaining 59% for $600M) Aug'2019, but website still operating independently. Bemdaneprocel got RMAT designation from FDA for PD as of May'24.4.26.91.00.60.81.11.13.84.31.01.01.001
40
Glyscendyes*noyesyesnonooperatingpill to mimic bariatric surgery (polymer that coats duodenum) for T2D, obesity, & NAFLD/NASH ph.2 trialsTxmetabolismT2D, obesity, NAFLD/NASH2duodenum liningpolymer drugpharmaSapan ShahBostonno152014$21.7paper & talk abstracts2024-08-222024-08-15*This counts as a calorie restriction mimetic.4.06.71.00.61.01.02.01.71.91.01.01.201
41
InSilico Medicineborderline*yesyesyesoperatingAI for drug discovery platform with particular focus on aging diseasesph.2 trials
Txbroad platformIPF, kidneyDs, cancer, Covid6TNIK, USP1, QPCTL, PHD, KAT6, 3CLprosmall moleculespharmaAlex Zhavoronkov, Feng RenChina, UAE, US, Canadano2682014$536200+ papers2024-08-182019*Mostly AI for drug discovery (like many companies not focused on aging) but also consistently focused on aging: publishing on aging, launching aging-focused sites, creating aging partnerships,spinning off aging companies, sponsoring & organizing aging conferences, & having longevity as part of mission on homepage.4.05.70.50.71.01.12.23.53.91.01.01.201
42
Vandriayesyesyesyesnooperatingtissue-specific small molecule mitophagy inductionpre-clinical
TxmitochondriaAD, PD, MCI, NASH, IPF, s-IBMundisclosed; similar to urolithin A's?small moleculespharmaKlaus DugiSwitzerlandno132021$322024-09-112024-08-26Hevolution (co-)led ~$30M series A round, Aug'24.3.94.31.00.91.01.10.61.62.21.01.01.001
43
Tranquis Therapeuticsyesnoyesyesyesoperatingmitochondria & lysosome drugs to modulate myeloid immune cells via regulating PGC1α, autophagy, lysosome acidity; esp but not only for neuro diseasesph.1 trials
Txmitochondria, autophagyALS, PD, AD, FTD, HD, MD, FA0PGC1α, lysosome aciditysmall moleculespharmaFrederic Godderis, Edgar EnglemanSFno82016$301 pub,
2 presos
2024-09-022022-06-29Last news from Aug'22 as of Sep'24.3.85.41.00.71.01.11.11.32.11.01.01.201
44
Brainstorm Cell Therapeuticsonly neuroyesyesyesnoyesoperatingautologous stem cells for neurodegeneration: MSCs differentiated to secret more neurotrophic factors (NTFs)ph.3 trials
Txstem cellsALS, MS, AD, PD, HD, ARDS, autism6cell therapypharmaChaim LebovitsIsraelyesBCLI$1029392004$63papers2024-09-282022-06-20Phase 3 trials for ALS completed as of 2024.3.84.20.50.91.01.13.32.31.51.01.01.201
45
Repair Biotechnologiesyesyesyesyesyesyesoperatingreverse atherosclerosis by directly breaking down (catabolizing) excess free cholesterol, first via LNP delivery of mRNApre-clinical
Txintracell junkhypercholesterolemia, MASH, atherosclerosisfree cholesterolmRNApharmaReasonSyracuse, NYno82018$202024-09-0420193.73.71.01.01.01.10.61.31.91.01.01.001
46
Vita Therapeuticsyesnoyesyesnoyes
operating status
cell replacement of defective cells via autologous & allogeneic iPSC-derived genetically engineered cell therapypre-clinical
Txstem cells / autologous & allogeneicmuscular distrophies, cancer0cell therapypharmaDouglas FalkDCno202019$65.7papers2024-08-272024-08-15Cambrian sub-company.3.66.01.00.61.01.10.61.92.61.01.01.201
47
Klotho Neurosciencesyesyesyesyesnonooperatingnovel truncated klotho variant via gene therapy or as recombinant protein biologicpre-clinical
TxklothoAD, PD, HD, CVD, KDklothobiologics, gene therapy / viralpharmaJoseph SinkuleyesKLTO$44342019$3.12025-06-102025-06-103.43.81.00.91.01.10.60.92.41.01.01.001
48
Minovia Therapeuticsyesyesyesnonoyesoperatingplacenta-derived allogeneic mitochondria for ex-vivo transplantation into stem cells (esp HSPCs), for mitochondrial diseases & agingph.1 trials
Txmitochondria, stem cellsPearson, MDS, KSS, CAR-T7CD34+ HSPCscell therapypharmaNatalie Yivgi-OhanaIsraelno302012$16.1Astellaspapers2024-08-1520193.66.01.00.61.01.11.12.11.81.01.01.201
49
Alectoronly neuroyes*yesnonooperatingcombat neurodegeneration w/ genetics + immunology + neurology; esp modulate microglia w/ insights from plasma & CSF biomarkers & volumetric MRIph.3 trials
Txbroad platformFTD, AD, PD, LBD11progranulin, TREM2, GPNMB, GCasepharmaSFyesALEC$1552442692013$270GSK, Abbviemany papers2024-07-312019*Mission is neurodegeneration, so within neuro-only focus, counts as aging since non-aging neuro indicatinos (TBI, genetic diseases) aren't a focus.3.65.90.50.61.01.13.33.53.11.01.01.201
50
LyGenesisyesnoyesyesnoyesoperatingallogeneic stem cells to use lymph nodes as in-vivo bioreactors to grow ectopic organs (eg liver, kidney, thymus, pancreas) instead of transplantsph.2a trials
Txstem cells / allogeneicliverDs, kidneyDs, T1D1hepatocytes engrafted to lymph nodescell therapypharmaMichael Hufford, Eric LagassePittsburghno62017$46liver 2; kidney 22024-08-012019Juvenencesce sub-company.3.66.01.00.61.01.11.51.12.41.01.01.201
51
Rejuvenation Technologiesyesyesyenyesyesyesoperatingextend telomeres via nucleoside-modfied TERT mRNA lipid nanoparticles, in vitro & in vivopre-clinical
Txtelomeres(I)PF, COPD, CLD, BMF/cytopeniatelomeraseRNApharmaJohn Ramunas, Glenn MarkovSFno202017$15.2papers2024-08-0720193.55.01.00.71.01.10.61.91.71.01.01.201
52
New Limityesyesyesyesoperatingepigenetic reprogramming discovery platform via single cell genomics, ML, & high-thru. func. assays to significantly extend healthspan, 1st for immune & liverpre-clinicalTxepigeneticpharmaBlake Byers, Brian Armstrong, Greg Johnson, Jacob KimmelSFno292022$1702024-08-052022-06-20Lots of details shared in the operating plan.3.55.81.00.61.01.00.52.13.21.01.01.001
53
Endogena Therapeuticsyesnoyesyesnoyesoperatingdrug discovery platform for small molecule regulators of endogenous stem/progenitor cellsph.2a trials
Txstem cellsRP, dAMD, IPF1see papersmall moleculespharmaMatthias StegerZurichno72016$29only linked pub2024-08-042021-05-06Rejuveron sub-company.3.45.71.00.61.01.11.51.22.11.01.01.201
54
Deciduous Therapeuticsyesyesyesyesyesoperatingactivate endogenous immune system mechanism to clear senescent cellspre-clinicalTxsenescenceIPF mentionediNKT cellssmall moleculespharmaRobin MansukhaniSFno162018$16.5key 2021 paper2024-08-032019May 2021 news article:
https://www.statnews.com/2021/05/10/reawakened-immune-cells-show-promise-in-mice-against-senescent-cells/
3.44.81.00.71.01.00.51.71.81.01.01.201
55
Akero TherapeuticsyesnoyesnononooperatingFGF21 mimetic, an engineered protein called efruxifermin (EFX)ph.3 trials
TxmetabolismMASH6FGF21biologicspharmaAndrew ChengSFyesAKRO$4,126606720172024-11-232024-10-253.311.11.00.31.01.13.32.65.21.01.01.001
56
SENISCAyesyesyesyesyesoperatingreverse cell senescence by modulation of RNA alternative splicingpre-clinicalTxsenescence, splicingoligonucleotidespharmaSarah Cole, Lorna Harries, Ben LeeExeter, UKno212020$11papers2024-09-032020-09-013.34.71.00.71.01.00.51.91.51.01.01.201
57
TNF Pharmaceuticals (was MyMD)yesyesyesnononooperatingsmall molecule TNF-α inhibitor and synthetic CBD analogph.2 trials
Txinflammationsarcopenia, RA, epilepsy3TNF-αsmall moleculespharma
Baltimore, MA
yesTNFA$26102014$22papers2024-07-272023-06-01Raising more private money, new $14M w/ room for more as of May'24. Positive phase 2 data reported summer'23.3.05.11.00.61.01.12.21.40.61.01.01.201
58
Intervene ImmuneyesyesyesTBD*yesyesoperatingreverse thymus involution & immune aging via HGH + DHEA + metformin via human trialsph.2 trialsTxstem cells1pharma / existing combosGreg Fahy, Robert (Bobby) BrookeLAno62013$0.5a few on homepage2024-09-042019*Should affect multiple diseases, but not targeting any specific diseases clinically yet.3.14.01.00.81.01.02.01.10.21.01.01.201
59
Epirium Bioyesnoyesyesnooperatingsmall molecule platform for muscle, regeneration, & mitochondriapre-clinical
TxmitochondriaIPF, sarcopenia, SMA15-PGDH / PGE2small moleculespharmaRussell CoxSDno162008$912024-09-012024-08-153.05.11.00.61.01.10.61.72.81.01.01.001
60
Ossium Healthyesyesnonoyesoperatingallogeneic cell therapies from (deceased human donor) bone marrow for hematologic diseases, organ rejection & bone matrix allografts for musculoskeletal defectsph.2 trials,
commercial
Txstem cells / allogeneicGVHD, multivisceral transplant, musculoskeletal defects9CD34+ cellscell therapypharmaKevin Caldwell, Erik WoodsSF, Indianapolisno992016$137
OssiGraft
papers2024-08-122024-08-122.99.71.00.31.01.12.22.93.11.01.01.201
61
Thymmune TherapeuticsyesyesyesnoyesoperatingiPSC thymus cell engineering/manufacturing platform generate to off-the-shelf (presumably allogeneic) cells at scalepre-clinicalTxstem cells / allogeneiccell therapypharmaStan WangBostonno212019$422024-10-162024-08-15Inejction into muscle & new thymic tissue develops there (so ectopic).2.84.71.00.61.01.00.51.92.31.01.01.001
62
Rejuvenate Bioyesyesyesyesnonooperatingliver directed (combo) gene therapy for dogs & humans for age-related diseasespre-clinical; vet clinical trials
Txmetabolism and/or cell communication?, klothodogs: MVD, obesity, KF, OA; humans: ACM, HF, FPL, obesity, MASHdogs, humansFGF21, αKlotho, sTGFβR2, AAVgene therapyveterinary, pharmaDaniel Oliver, Noah Davidsohn, George ChurchSDno142017$192 at bottom2024-08-172019Not to be confused with Rejuvenate Biomed.2.83.11.00.91.01.11.71.61.81.00.51.201
63
Shift Biosciencesyesyesyesyesyesoperatingreprogramming platform: AI/ML, custom single-cell transcriptomic aging clock, & wet lab tests to identify safe (max efficacy / least pluripotency) gene combospre-clinicalTxepigeneticpharmaDaniel IvesCambridge, UKno112017$22.52024-08-1620192.84.01.00.71.01.00.51.52.01.01.01.001
64
Pluri Inc (prev Pluristem)yesnoyesno*noyesoperatingplacenta-derived allogeneic stem cell expansion platform, first for muscle, hematological conditionsph.2 trials
Txstem cells / allogeneicmuscle injury, GVHD, radiation11placental derived stem cellscell therapypharmaYaky YanayIsrael, BrazilyesPLUR$391231832003$163papers2024-07-162022-06-29*Only muscle regen is really an aging diseases at present, but platform clearly has wider applicability so this will prob change to yes in future.2.799.31.00.31.01.12.23.22.31.01.01.201
65
GenFlow Biosciencesyesyesyesyesnonooperatinggene therapies (AAV-based) for aging in dogs & humans, esp relating to SIRT6, inc a centenarian SIRT6 variantpre-clinical*, vet pre-clinical
TxgenomicNASH/MASH, Werner, dog agingdogs, humansSIRT6gene therapy / AAVpharma, veterinaryEric LeireLondon, BelgiumyesGENF.L$3552020$1.3papers2024-09-042020-10-01*This page suggests they are close to starting phase 1.2.62.91.00.91.01.10.61.00.91.01.01.201
66
Tolerance Bioyesyesyesyesoperatingrestore thymus w/ adult stem cell / iPSC derived thymic epithellial cell transplants & thymic organoids; also drugspre-clinicalTxstem cellscell therapy, small moleculespharmaFrancisco LeonSDno102023$17.2papers2024-10-162024-10-162.694.51.00.61.01.00.51.41.81.01.01.201
67
Cleara Biotechyesyesyesyesnoyesoperatingsenolytics (esp vs 'scarred' SnCs), initially based on FOXO4, for healthspan & cancer, first for mutant-p53 cancerpre-clinical
Txsenescencecancer, liverDsp53peptidespharmaPeter de KeizerNetherlandsno132018$2.52024-09-0420192.62.91.00.91.01.10.61.60.81.01.01.001
68
CellVieyesyesyesnoyesoperatingallogeneic mitochondria transplantation 1st for ischemia-reperfusion injury, esp arising via kidney transplant, then broader agingpre-clinicalTxmitochondriakidney transplantcell/organelle therapypharmaAlex SchuellerZurich, Switzerlandno112018$112024-09-052022-06-28Transplanted mitochondria enter cells via endocytosis & merged with the mito network.2.53.51.00.71.01.00.51.51.51.01.01.001
69
MetroBiotech (International)yesyesyesnonooperatingpharmaceutical NAD+ precursors & enhancersph.2 trialsTxmitochondria / NAD+T2D, diabetic kidney disease, Covid, FA4pharmaDavid Livingston, David Sinclair*no92014unknownmix from company +external2024-09-032024-08-15*David Sinclair is often mentioned as a founder & SAB member, and lists the company on his LinkedIn page (thru 'present'), but he's not currently listed on the company website as of Sep'24.2.44.01.00.61.01.02.01.40.01.01.01.201
70
Morphoceuticals Incyesyesyesnoyesoperatingbioelectrics, together with multi-omics & AI, for tissue repair and organ regenerationpre-clinicalTxstem cells*pharmaJim Jenson, Michael LevinBostonno62020$14.5papers2024-10-182021-05-12*Not based on stem cells, but "stem cells" is the categorical term used on this site for regenerative med (replentishing cell loss), which is the best-fit category for this company.
Juvenescence sub-company.
2.44.01.00.61.01.00.51.11.71.01.01.201
71
ImmuneAGE Bioyesyesyesyesyesyesoperatingimmune system rejuvenation drug platform via 1000x HSC expansion enabling screening & better BMT; also mitophagy & mitochondria biogenesis small moleculepre-clinical
Txstem cells, mitochondriaARIs, BMT (MM), HSC banking (pre-chemo)similar to Urolithin A's? (source)*small molecules, cell therapypharmaSebastian A. Bunemeierno62022$22024-09-112024-08-15*Also a patent here.2.32.31.01.01.01.10.61.10.71.01.01.001
72
GenSight Biologicsyes*noyesnonoyesoperatingallotopic expression of mito gene ND4 in nucleus w/ mRNA delivery to mito membrane; also optogenetics system; for retinal diseases via AAV gene therapyph.3 trials
TxmitochondriaLHON, RP, dAMD9mito ND4 genegene therapy / viralpharmaLaurence Rodriguez Paris, NYCyesSIGHT.PA$1816382012$264LUMEVOQ2024-07-262019*Allotopic expression of mtDNA w/ mito delivery could rescue general mito aging. This is farthest along allotopic exp clin prog tho for genetic disease. Had notable ph.3 fails 2018-19 inc unusual fail due to improved vision in control eye. Now pursuing new ph.3 involving treating both eyes.2.27.41.00.31.01.13.32.31.81.01.01.001
73
Revel
Pharmaceuticals
yesyesyesyesyesoperatingplatform for designing enzymes to repair drivers of aging & disease: accumulation of toxic proteins or metabolites esp. AGEspre-clinicalTxECMRACML, citrulline, glucosepane, carbamylationenzymespharmaAaron CravensSFno72019$10.72024-08-20201916min presentation at 2024 Rejuvenation Startup Summit in Berlin.2.33.21.00.71.01.00.51.21.51.01.01.001
74
Lineage Cell Therapeuticsyesnoyesnonoyesoperatingallogeneic transpalntation of cells terminally differentiated f/ reproducible pluripotent stem cellsph.2 trials
Txstem cells / allogeneicdry AMD, SCI, hearing loss2RPE cells, OPCscell therapypharmaSDyesLCTX$22868321990$109GenentechOpRegen2024-07-272022-09-232.37.71.00.31.01.12.22.23.41.01.01.001
75
Transposon Therapeuticsonly neuroyesyesTBDyesnooperatingnucleoside inhibitors of LINE-1 reverse transcriptase (NRTIs) & other LINE-1 modulation (eg Protein Kinase R inhibitors, PKRs) for neurodegenerative diseasesph.2 trials*
TxgenomicPSP, ALS, FTD, AGS, AD3LINE-1small moleculespharmaDennis PodlesakSDno52019$59.12censavudine2024-08-122024-08-12*Final results press release announcement from phase 2 trial for ALS, Jul'24.2.22.90.50.81.01.12.21.02.51.01.01.001
76
Neuralyonly neuroyes*yesnonooperatingneurodegeneration 1st via GLP-1R agonist that targets microglia/astrocytes-induced neuroinflammation w/ preclinical efficacy in PD & AD modelsph.2 trials
Txinflammation?PD, AD, stroke5GLP-1 (in microglia/ astrocytes)small molecules?pharmaSeulki Lee, Ted Dawson, Viktor RoschkeDCno162016$36papers (at bottom)2024-08-202024-08-15*Mission is neurodegeneration, so within neuro-only focus, counts as aging since non-aging neuro indicatinos (TBI, genetic diseases) aren't a focus.
Subsidiary of D&D Pharmatech
2.23.70.50.61.01.12.21.72.21.01.01.201
77
Covalent Bioscienceyesyesyesyesnoyesoperatingcatalytic antibodies (catabodies) for aging (1st for ATTR, Aβ, & tau) & electrophilic vaccines (1st for HIV)pre-clinicalTxproteostasisCVD, AD, HIVATTR, Aβ, taubiologicspharmaHoustonno42011$2.0papers2024-10-042019Feb'24 article suggests current activity & seeking funding, but "recent news" page on website has no news since Jun'19.2.22.51.00.91.01.00.50.90.71.01.01.201
78
Klotho Therapeuticsyesyesyesyesnonooperatingrecombinant klothopre-clinicalTxklothoneuroDs, kidneyDs, cancer, diabetesklothobiologicspharmano22016$102024-07-292024-07-292.22.41.00.91.01.00.50.41.51.01.01.001
79
Ponce Therapeuticsyesyesyesyesnoyesoperating2 senolytics for epithelial & mesenchymal SnCs & SASP-suppressing tyrosine kinase inhibitor senomorphics pre-clinical
Txsenescencewrinkles, cataractsCaspase-9; JAK2/3//TYK2peptides, small molecules?pharmaKevin SlawinHoustonno82019$1.52024-08-232024-08-23Both topical (skin) & systemic programs.
Not to be confused with Ponce de Leon Health (Rejuvant)
2.22.41.00.91.01.10.61.30.61.01.01.001
80
HCW Biologicsyes*yesysenonoyesoperatingimmune platform to disrupt inflammaging: rejuvenate immune sys, clear senescent cells, & modulate inflammasomes via multi-/bispecific fusion proteinsph.2 trials
Txinflammation, senescencecancer, autoimmune, infectious2TGF-β, IL-15, IL-2, IL-7, IL-21biologicspharmaHing C. WongMiamiyesHCWB$945292018$68papers; posters2024-08-182024-08-15*Lead indication is cancer but they think lead asset also has dual senescence MoA: clears senescent cells & modulates SASP. See 2023 paper in Aging Cell & this page. 2024 settled lawsuit giving ImmunityBio rights to lead HCW9218 for some cancer indications but HCWB retains "exclusive worldwide rights [..] HCW9218 for aging-related diseases other than cancer."2.16.81.00.31.01.12.22.11.41.01.01.201
81
MitoRX Therapeuticsyes*noyesyesnonooperatingmitochondria small molecules regulating sulfide-signaling: substrate replenishment for trans-sulfuration deficiency pre-clinical
TxmitochondriaDMD, obesity, COPD, HD, AD, PD, CBS-def, CMT2Asmall moleculespharmaJon Rees, Matt WhitemanLondon, Oxford, UKno142021$6.92024-09-012024-08-15*Rare mito diseases are initial focus, but technology applicable to neurodegeneration & mito aging broadly.2.13.51.00.61.01.10.61.61.31.01.01.001
82
Longevity Biotechyes*noyesyesnonooperatingsynthetic orally available peptide platform, esp for neuroinflammatory diseasesph.1 trials
Txinflammation, metabolismPD, neuroinflammation, diabetes, cancer2B-GPCR, VIP, GLP-1, GIPpeptidespharmaScott ShandlerPhiladelphiano62010$1.9several2024-09-032019*Longevity in company name refers to stability of the peptides, not longevity of the patient. Nonetheless, the targets/MoAs include age related areas of neuroinflammation & nutrient sensing, plus all indications are age-related diseases as of Sep'24, despite that aging/longevity doesn't seem to be a company focus.2.13.41.00.61.01.11.11.10.71.01.01.201
83
Samsara Therapeuticsonly neuroyesyesyesnonooperatingsmall molecule autophagy activators screening platform via iPSC testing for neurodegenerationpre-clinical
TxautophagyneuroDsTDP-43, α-synuclein, PMP-22small moleculespharmaOxford, UKno232018$252024-08-022019Not to be confused with public software company Samsara.2.02.30.50.91.01.10.61.92.01.01.01.001
84
Fauna Bioyes*no*yesyesoperatingcomparative animal genomics & multi-omics for drug discovery biased to human druggable targets to generally improve human health inc. longevity areaspre-clinicalTxbroad platform** (see notes)pharmaAshley Zehnder, Katie Grabek, Linda GoodmanSFno282018$13pubs at bottom2024-07-282019*Central idea & mission phrased more generally for human health in any area but many lead areas specifically important in aging & longevity mentioned explicitly as an area in a few places
** Takes inspiration/bio from other species but target species is still humans.
2.05.11.00.41.01.00.52.11.71.01.01.201
85
Pretzel Therapeuticsyes*noyesnonooperatingupregulate mtDNA for mitochondria health, 1st for genetic mitochondria diseases but also for age-related conditionspre-clinicalTxmitochondriapharmaJay ParrishSweden, Bostonno492019$73papers2024-09-102024-08-15*Assuming yes based on generality of potential of upregulation of mtDNA, but if the company never goes beyond genetic mitochondria diseases, it may eventually be moved off of this list.2.06.71.00.31.01.00.52.42.71.01.01.201
86
Casma Therapeuticsyesnoyesnononooperatingdrug platform (using heterobifunctional chemistry) for modulating autophagy as a form of targeted degradation (autophagosome biogenesis around the target)pre-clinical
Txautophagycancer, PDTRPML1drugspharmaFrank GentileBostonno182018$183select type = pub2024-08-202023-05-292.06.71.00.31.01.10.61.83.21.01.01.201
87
Amplifier TherapeuticsyesyesyesnooperatingAMPK activatorsph.1b trials*
Txmetabolismcardiometabolic diseases0*AMPKsmall molecules?pharmaJames Hallno02022$332024-11-182024-08-15*Cambrian website pipeline image shows ph.1/2a for ATX-304 & Amplifier website pipeline shows just ph.2 but can't find trial on clinicaltrials.gov under either company name or ATX-304 as of Jul'24 so using press release of 1b as current clinical stage as of Aug'24.
Cambrian sub-company.
2.03.31.00.61.01.11.10.02.21.01.01.001
88
Arda Therapeuticsyesyesyesyesoperatingkilling pathogenic cells for chronic diseases & aging via single-cell data to identify bad cells & how to target them, then very targeted eliminationpre-clinicalTxpharmaAdam FreundSFno92021$8.52024-09-012024-08-152.03.31.00.61.01.00.51.41.41.01.01.001
89
Timelineyesyesyesyesnonooperatingnutraceutical MitoPure, a pure Urolithin A for mitochondria health (upregulates mitophagy)commercial, ph.2 trialsTxmitochondriafrailty/sarcopenia, wrinkles/skin-aging, COPD17Urolithin A's targets/MoA (↑mitophagy)supplementsnutraceuticals
Switzerland
no472007$80.3CHf64.4MitoPurepapers2024-09-032022-06-30Results of immune trial announced May'24. Formerly called Amazentis (or that might still be a corporate parent company).1.92.11.00.91.01.02.02.42.71.00.31.201
90
Praetegoyesyesyesyesnonooperatingclass of BBB-penetrant small molecules (Amadorins) that inhibit AGEs, esp for neurodegeneration, esp ADpre-clinicalTxECMAD, DPN, DRsmall moleculespharmaPepper Landsonno22017$5.92024-09-042024-08-151.92.11.00.91.01.00.50.41.21.01.01.001
91
Cyclarity (was Underdog)yesyesTBDnoTBDyesoperatingcyclodextrin derivatives to remove 7-ketocholesterol to remove arterial plaquespre-clinicalTxintracell junkatherosclerosis, heart attack, stroke7-ketocholesterol (7KC)drugspharmaMatthew ‘Oki’ O’Connor, Michael KopeSFno142019$182021; 20202024-08-0220191.94.71.00.41.01.00.51.61.81.01.01.201
92
Booster Therapeuticsyesyesyesnooperatingsmall molecules to boost the activity of 20S proteosomes (whose activity declines with age) for proteostasispre-clinicalTxproteostasis20S proteosomesmall moleculespharmaDiogo R. Felecianono42020$152024-10-212024-10-17Apollo VC invested.1.93.11.00.61.01.00.50.91.71.01.01.001
93
Cyclo Therapeuticsborderline*noyesnonoyes?operatinghydroxypropyl beta cyclodextrin for cholesterol transport, first for AD & Niemann-Pickph.3 trials
Txintracell junkNiemann Pick, AD6cholesteroldrugspharmaN. Scott FineGainesville, FLyesCYTH$4,6478181990$17Trappsol Cyclopapers2024-08-022022-06-01*Yes tentatively based on likely breadth of platform applicability.1.96.20.50.31.01.13.31.85.21.01.01.201
94
Elastrin Therapeuticsyesnoyesyesyesoperatingdrug plattform for damaged elestin: nanoparticle with drug + elastin antibody for targetingpre-clinicalTxECMMarfan, COPD, cardiovascularDselastinpharmaNaren Vyavahare
Greenville, SC
no92017$21papers2024-09-042022-06-281.84.51.00.41.01.00.51.41.91.01.01.201
95
Vincere Biosciencesyesyesyes yesoperatingsmall molecule mitophagy upregulation, esp for PD, via USP30 inhibition or Parkin activationpre-clinicalTxmitochondriaPD, kidneyDs?USP30, Parkinsmall moleculespharmaSpring Behrouz, Andy LeeBostonno102018$1.82024-09-072024-08-15Talks by & on the company abound, eg 2024 Dublin Longevity Summit. Spun out of NeuroInitiative.1.82.61.00.71.01.00.51.40.61.01.01.001
96
Renewal Bioyesyesyesyesyesoperating"renew humanity - making all of us young and healthy"pre-clinicalTxstem cells*pharma?Israelno142022unknown
2021 paper
2022 paper
2023-05-272023-05-29*Replacement cell/organ source technology company, including as stem cell source but also replacement tissue/organs. "Stem cells" is the categorical term used on this site for regenerative med (replentishing cell loss) even if not based on stem cells.1.82.61.00.71.01.00.51.60.01.01.01.200
97
GEn1E Lifesciencesyesnoyesnononooperatingdrug discovery platform for inflammatory diseases, lead is p38α kinase inhibitorph.2 trials
TxinflammationARDS2p38α:MK2, ERK 1/2drugspharmaSFno152018$172024-08-032019*Website doesn't really talk about aging, just inflammation, but main target p38 clearly age related.1.75.71.00.31.01.12.21.71.81.01.01.001
98
ChromaDexyesyesyesyesno*nooperatingnutraceuticals for aging, esp. Tru Niagen w/ nicotinamide riboside (NR), an NAD+ precursorcommercial,
ph.4 trials
Txmitochondria / NAD+cancer, MCI, HF,
mitoDs, more...
43NAD+supplementsnutraceuticalsRobert Fried, Charles BrennerLAyesCDXC#N/A1061291999$85Tru Niagenpapers2024-07-162019*Charles Brenner attends a few conferences but more as a scientist than company rep & not the execs or company as sponsor/presenter.1.71.91.00.91.01.00.53.02.81.00.31.201
99
Mitrixyesyesyesyesyesoperatingmitochondria transplant of bioreactor-grown "young" mitochondriapre-clinicalTxmitochondriacell/organelle therapypharmaTom BensonSFno92018$0.3papers2024-09-0720191.72.41.00.71.01.00.51.40.11.01.01.201
100
Cerevanceonly neuronoyesnonooperatingdrug discovery platform based on sequencing of post-mortem human brain tissue: transcriptome diffs by age, cell type, region, & diseaseph.3 trials
Txbroad platformPD, AD, ALS, obesity10GPR6, Ox1R, KCNK13, THIK-1small moleculespharmaCambridge, UKno612016$204Solengepraspapers2024-09-2020191.65.50.50.31.01.13.32.63.31.01.01.201